Dr Zahra Rattray
Senior Lecturer
Strathclyde Institute of Pharmacy and Biomedical Sciences
Personal statement
Senior Lecturer in Translational Pharmaceutics I am a pharmacist by training with experience of working within the hospital, community and industry sectors. I have contributed to a diverse molecule portfolio spanning pre-clinical to late-stage development during my time at AstraZeneca and in collaboration with Patrys Ltd at the Yale School of Medicine (PAT-DX1). My research team has two overall interests; i) Analytical characterization of parenteral formulation attributes and in vivo performance: A key challenge in the commercial translation of newly-discovered drugs is understanding the key performance indicating characteristics crucial to their biological performance and how they interact with living systems. We are interested in developing new tools to profile these performance characteristics. Areas of research interest in my lab are summarized as follows; Understanding the environmental and physicochemical determinants of solution-phase formulation stability for antibody and suspension formulations. Determining key critical quality attributes in particle design to inform optimal in vivo performance. Analytical evaluation of nanomedicine interaction with biological media, and the mechanism of cellular uptake in two- and three-dimensional cellular models. Applying novel imaging modalities for evaluating drug and nanoparticle biodistribution, and impact on tumor response. The interplay between the tumour microenvironment and nanomedicine in vivo performance with a view to developing biorelevant in vitro tests. ii) DNA repair agents and the nuclear import pathway, and their role in cancer: We are interested in screening the functional and phenotypic role of DNA repair mutations. We also develop new small molecule drugs against various nuclear import transporters known to be elevated in cancer.
Area of Expertise
Expertise
I am an interdisciplinary pharmaceutical researcher with experience in developing injectable drugs (antibodies, small molecules, and nanomedicines). I have significant expertise in the analytical characterization of critical quality attributes for these products and the design of pre-clinical studies for evaluating biological performance (biopharmaceutics).
Equipment Capabilities
My laboratory hosts a Malvern Panalytical NanoSight NS300 and Archimedes Resonant Mass Measurement, which are both used to measure particle size and concentration. If you would be interested in accessing these technologies, please get in touch (zahra.rattray@strath.ac.uk).
I am also Director for the new EPSRC Multiscale Metrology Suite (modular setup including Field Flow Fractionation, Inductively-coupled mass spectrometry, Light Scattering and Raman) for Next-Generation Health Nanotechnologies (EP/V028960/1). For more information or to access this facility, please get in touch.
Prize And Awards
- Fellow of the Royal Pharmaceutical Society
- Recipient
- 11/2024
- Strathclyde Teaching Excellence Award 2024 for Faculty of Science Breaking Barries
- Recipient
- 8/2024
- Member of the University Court
- Recipient
- 8/2024
- Fellow of the Royal Pharmaceutical Society (FRPS)
- Recipient
- 2024
- Fellow of Royal Society of Edinburgh Young Academy of Scotland (RSE-YAS)
- Recipient
- 2024
- University of Strathclyde Medal for Faculty of Science Breaking Barriers 2024
- Recipient
- 2024
Publications
- Sex differences in colon cancer metabolism reveal a novel subphenotype
- Cai Yuping, Rattray Nicholas J W, Zhang Qian, Mironova Varvara, Santos-Neto Alvaro, Hsu Kuo-Shun, Rattray Zahra, Cross Justin R, Zhang Yawei, Paty Philip B, Khan Sajid A, Johnson Caroline H
- Scientific Reports Vol 10 (2020)
- https://doi.org/10.1038/s41598-020-61851-0
- ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody
- Rattray Zahra, Deng Gang, Zhang Shenqi, Shirali Anupama, May Christopher K, Chen Xiaoyong, Cuffari Benedette J, Liu Jun, Zou Pan, Rattray Nicholas JW, Johnson Caroline H, Dubljevic Valentina, Campbell James A, Huttner Anita, Baehring Joachim M, Zhou Jiangbing, Hansen James E
- JCI Insight Vol 6 (2021)
- https://doi.org/10.1172/jci.insight.145875
- Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty
- Rattray Nicholas JW, Trivedi Drupad K, Xu Yun, Chandola Tarani, Johnson Caroline H, Marshall Alan D, Mekli Krisztina, Rattray Zahra, Tampubolon Gindo, Vanhoutte Bram, White Iain R, Wu Frederick CW, Pendleton Neil, Nazroo James, Goodacre Royston
- Nature Communications Vol 10 (2019)
- https://doi.org/10.1038/s41467-019-12716-2
- Evaluation of temporal aggregation processes using spatial intensity distribution analysis
- Rattray Zahra, Zindy Egor, Buzza Karen M, Pluen Alain
- Protein Self-Assembly Methods and Protocols (2019) (2019)
- https://doi.org/10.1007/978-1-4939-9678-0_11
- Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications
- Rattray Zahra, Dubljevic Valentina, Rattray Nicholas, Greenwood Deanne L, Johnson Caroline H, Campbell James A, Hansen James E
- Biochemical and Biophysical Research Communications Vol 496, pp. 858-864 (2018)
- https://doi.org/10.1016/j.bbrc.2018.01.139
- A DNA-damaging lupus autoantibody synergizes with PARP inhibitors against DNA repair-deficient tumor cells
- Rattray Zahra, Patel Jaymin M, Noble Phillip W, Dubljevic Valentina, Greenwood Deanne L, Campbell James A, Hansen James E
- Cancer Research Vol 78, pp. 2773 (2018)
- https://doi.org/10.1158/1538-7445.AM2018-2773
Professional Activities
- EPSRC Peer Review College (External organisation)
- Member
- 6/7/2021
- Royal Society of Edinburgh's Young Academy of Scotland (External organisation)
- Chair
- 4/2021
- The developability of monoclonal antibody based therapies
- Speaker
- 15/5/2025
- Novel analytical pipelines for understanding oligonucleotide-loaded lipid nanoparticle critical quality attributes
- Speaker
- 14/3/2025
- Metrology to support sustainable development of nanotherapeutics
- Speaker
- 16/1/2025
- Correlating antibody-drug conjugate quality attributes with biological performance
- Speaker
- 16/1/2025
Projects
- DTP 2224 University of Strathclyde | Almawazini, Mohammad
- Rattray, Nicholas (Principal Investigator) Rattray, Zahra (Co-investigator) Almawazini, Mohammad (Research Co-investigator)
- 01-Jan-2025 - 01-Jan-2028
- Host for Telma Caneca
- Rattray, Zahra (Principal Investigator)
- 15-Jan-2025 - 14-Jan-2025
- Predicting and controlling High Order Structures for the development of more effective and safer therapeutic peptides (ICASE)
- Rattray, Zahra (Principal Investigator) Burley, Glenn (Co-investigator)
- 01-Jan-2024 - 30-Jan-2028
- Industrial CASE Account - University of Strathclyde 2024 | Paszczuk, Lauren
- Burley, Glenn (Principal Investigator) Rattray, Zahra (Co-investigator) Paszczuk, Lauren (Research Co-investigator)
- 01-Jan-2024 - 01-Jan-2028
- Exploration of the interaction between patient clinical history and CAR-T quality parameters on clinical outcomes
- Rattray, Zahra (Principal Investigator)
- 01-Jan-2024 - 30-Jan-2030
- Industrial CASE Account - University of Strathclyde 2024 | Salvadori, Irene
- Rattray, Zahra (Principal Investigator) Burley, Glenn (Co-investigator) Salvadori, Irene (Research Co-investigator)
- 01-Jan-2024 - 01-Jan-2028
Contact
Dr
Zahra
Rattray
Senior Lecturer
Strathclyde Institute of Pharmacy and Biomedical Sciences
Email: zahra.rattray@strath.ac.uk
Tel: 548 2106